Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>TRAEs (reported as PTs) in ≥20% of patients, grade ≥3 TRAEs in ≥5% of patients, and AESIs in ≥10% of patients in the dose-expansion phase.</p>
Պահպանված է:
Նմանատիպ նյութեր
-
Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
: Kristoffer Staal Rohrberg (15009138)
Հրապարակվել է: (2025) -
Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
: Kristoffer Staal Rohrberg (15009138)
Հրապարակվել է: (2025) -
Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
: Kristoffer Staal Rohrberg (15009138)
Հրապարակվել է: (2025) -
Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
: Kristoffer Staal Rohrberg (15009138)
Հրապարակվել է: (2025) -
Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
: Kristoffer Staal Rohrberg (15009138)
Հրապարակվել է: (2025)